Brahim Gargouri

Bioneer A/S is an innovative Research and Technology Organization with a history of more than 40 years. Bioneer is a subsidiary of the Technical University of Denmark and approved by the Danish Ministry of Higher Education and Science as an authorised provider of services within biomedicine and biotechnology. Bioneer has two main focus areas; 1) in vitro models and 2) recombinant protein expression 1) Bioneer has worked extensively on the development and implementation of technologies within in vitro model systems and since 2000 especially in the field of stem cell derived neural model systems and immuno-oncology. Bioneer has developed and implemented iPSC platforms and gene editing technology platforms and a variety of neural differentiation protocols, including several in vitro models for Alzheimers Disease and Parkinson Disease. Within immuno-oncology Bioneer has established a range of spheroid-based cancer models that mimic the tumormicroenvironment, 2) Bioneer has for decades developed and produced recombinant proteins using both mammalian and microbial hosts. Our cell line development team of dedicated scientists is implementing state-of-the-art innovative methods to enhance protein manufacturing. We focus on advancing techniques that improve yield, purity, and efficiency, driving progress in therapeutic proteins, including new protein modalities, like bispecific antibodies and protein-drug-conjugates (PDCs). Bioneer has extensive experience in commercial exploitation of in vitro model systems, including disease –and toxicity platforms and recombinant protein expression technologies, to industry and the research community.